Petros Grivas, Clinical Director of the GU Cancer Program at the University of Washington, shared a post by ECOG-ACRIN Cancer Research Group on X, adding:
“Hope you can open this important phase 3 trial ECOG-ACRIN Cancer Research Group 8231 with SG/Pembrolizumab vs salvage chemotherapy in pts with anti-PD(L)1 resistant advanced urothelial Carcinoma.”
Quoting ECOG-ACRIN‘s post:
“Monika Joshimd and Petros Grivas are leading Clinical Trial EA 8231, a phase 3 randomized trial comparing the effectiveness of pembrolizumab and sacituzumab govitecan to standard-of-care chemo in patients with advanced Urothelial Cancer.”
More posts featuring Chemotherapy on OncoDaily.